Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling

Celldex Therapeutics, Inc.

2024-FY EPS reported -$2.45 revenue$7,020,000

Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.
Q4 2024 net loss $47.1M ($0.71/sh) vs $43.3M ($0.83/sh) Q4 2023; R&D expenses $46.9M.
Phase 3 CSU studies EMBARQ-CSU1/2 enrolling ~915 patients each across 40 countries.
Phase 3 CIndU program expected to start in 2025; Phase 2 EoE study fully accrued.
Phase 1 CDX-622 (SCF/TSLP bispecific) initiated; multiple data readouts expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.